QiG INS Conference May 22, 2011
|
|
- Moses Lamb
- 5 years ago
- Views:
Transcription
1 Strategy & Vision Growth Electrochem Medical Device Evolution QiG Cardio vascular QiG INS Conference May 22, 2011 Greatbatch Medical Neuro modulation 1
2 GREATBATCH TODAY 2010 Revenue by Product Line NYSE: GB (IPO 2000) Founded 1970 Corporate Headquarters in Clarence, NY $550 Million Diversified Revenue Base Global Footprint 3,000 Dedicated Associates CRM & Neuromodulation Orthopaedics Vascular Access Electrochem 2010 Revenue by Geographic Area North America Europe Rest of World 14% 7% 22% 3% 34% 57% 63% STRATEGY & VISION 2
3 Greatbatch will be the definitive leader in critical technologies by infusing integrity, innovation and operational excellence into the medical device and commercial markets. STRATEGY & VISION 3
4 GREATBATCH MEDICAL IS FOUNDATIONAL TO THE MEDICAL DEVICE STRATEGY Innovation Operational Excellence Quality & Regulatory Customer Partnerships STRATEGY & VISION 4
5 GREATBATCH MEDICAL 95% of all pulse generators implanted worldwide contain one or more Greatbatch Medical component STRATEGY & VISION 5
6 QiG MISSION STATEMENT QiG s mission is to empower the creative design, development and speed to market of new medical devices in strategic markets that utilize and complement the inherent strengths of Greatbatch, Inc. We will focus our energies in the therapy fields of Cardiovascular, Neuromodulation and Orthopaedics by partnering with key opinion leaders, creating new medical device products for our OEM customers and by incubating companies of our own. QiG 6
7 MARKET AREAS OF FOCUS CARDIOVASCULAR NEUROMODULATION ORTHOPAEDIC QiG 7
8 MULTIPLE AVENUES OF DEVELOPMENT Investment Mechanism Partner Risk Level Return Potential Strategic Investment Entrepreneur/ Early Stage Company Moderate Moderate to High OEM Customer Discrete Projects OEM Customers Low Moderate (Capitated) Medical Device Incubation Clinicians (KOLs) High High QiG 8
9 QiG RESOURCES 120 Professionals with Proven Medical Device Experience Minneapolis Clarence Denver Cleveland Dallas QiG 9
10 QiG BUSINESS MODEL Sales & Distribution by OEM Partners Concept QiG Group Detailed Design Medical device development Verification & Validation Regulatory QiG Focuses On Niche markets Device Manufacturing Quality Assurance Sterilize Pack License or Technology Sale Dedicated research & development Innovative system design Proven device-level experience World renowned physician partners Concentrated regulatory risk Intellectual property QiG 10
11 11 11 QiG NEW PIPELINE OPPORTUNITIES Intelect Medical Algostim OAB Sleep Apnea DBS Chronic Pain Obesity Headache Antithrombotic Radial Access Sheath OptiSeal Valved Introducer Transseptal Steerable Sheaths MRI Transcatheter Valve Repair Antimicrobial coatings Disease Monitoring Obesity Neuromodulation Cardiovascular Orthopaedics TBD TBD MIS Disposable Sensors Modular System Spine Im plant
12 FINDING THE BEST OPPORTUNITIES: QiG SCREENING PROCESS Market Therapy Leadership Financial Hurdle Rates Go/No-Go Mechanisms System Design Intellectual Property Regulatory/ Clinical/ Reimbursement Kill Switch QiG 12
13 SUMMARY A natural evolution of our capabilities Founded on a disciplined, diversified portfolio approach Greatbatch has been executing on this strategy for three years Solidifies & deepens our partnerships with current customers Funded internally from strong cash flow generation Designed to raise the growth & profitability profile of the company QiG 13
14 Indication: Spinal Cord Stimulation for the treatment of chronic pain of the trunk and limbs 14
15 NEUROMODULATION DEFINED Neuromodulation is the therapeutic alteration of activity in the central, peripheral or autonomic nervous systems, electrically or pharmacologically, by means of implanted devices.* *Definition courtesy of the North American Neuromodulation Society (NANS) NEUROMODULATION 15
16 NEUROSTIMULATION MARKET REVENUES (WW) VNS $ : $2,160 mm 2014: $3,680 mm Other $95 Total Market CAGR: 14% (10% - 27%) VNS $310 Other $172 SNS $270 SNS $600 DBS $315 SCS $1,300 SCS $2,000 DBS $600 Source: Neuromodulation company earnings releases and estimates Excludes cochlear, drug pumps, external stimulation SCS: Spinal Cord SNS: Sacral Nerve DBS: Deep Brain VNS: Vagus Nerve NEUROMODULATION 16
17 # of Units NEUROSTIMULATION SYSTEM GROWTH (WW) 180, , ,000 90,000 60,000 30, ,500 10,000 15,000 10,500 65,000 CAGR: 14% 131,707 13,225 22,326 14,620 81, ,556 17,222 33,333 20, ,000 VNS SNS DBS SCS 0 Estimates from Global Data report SCS: Spinal Cord SNS: Sacral Nerve DBS: Deep Brain VNS: Vagus Nerve NEUROMODULATION 17
18 NEUROSTIMULATION TARGETS & MARKETS FDA APPROV ED Spinal Cord Stim: Pain Sacral Nerve Stim: Urinary Incontinence Deep Brain Stim: Parkinson s Disease, Dystonia, Essential Tremor, Depression, Epilepsy, Obsessive Compulsive Disorder Vagus Nerve: Depression, Epilepsy NEUROMODULATION EMERGING Deep Brain Stim: Obesity, Stroke Recovery, Epilepsy Cortical Stim: Epilepsy Peripheral Nerve Stim: Migraine, Extremity Pain Carotid Artery, Sinus Stim: Hypertension Spinal Cord Stim: Angina Gastric Stim: Obesity Sacral & Pudendal Nerve: Interstitial Cystitis Sacral Nerve Stim: Fecal Incontinence FUTURE Deep Brain Stim: Alzheimer s, Anxiety, Bulimia, Tinnitus, Traumatic Brain Injury, Tourette s, Sleep Disorders, Autism, Bipolar Vagus Nerve: Alzheimer s, Anxiety, Obesity, Bulimia, Tinnitus, Obsessive Compulsive Disorder, Heart Failure Spinal Cord Stim: Asthma Gastric Stim: Bulimia 18
19 DISEASE PREVALENCE & INCIDENCE (U.S.) FDA APPROVED INDICATIONS DISEASE THERAPY PREVALENCE (mm) COST TO TREAT ($bln) INCIDENCE PER YEAR Pain SCS 75.0 $ ,000 Incontinence SNS 33.0 $ ,000 Parkinson s / Essential Tremor DBS $2.6 $2.0 50,000 70,000 Epilepsy VNS 3.0 $ ,000 NEUROMODULATION Information from mulitple sources 19
20 THERAPY DELIVERY & SYSTEM ELEMENTS Stimulation Leads Patient & Clinician Programmers Implantable Pulse Generator IPG Recharger NEUROMODULATION 20
21 CAPABILITIES REQUIRED System Specs System Design ISO / Quality Risk Mgmt Labs Tech Writing Package Design NEUROMODULATION 21
22 QiG CAPABILITIES System Specs System Design ISO / Quality Risk Mgmt Labs Tech Writing Package Design NEUROMODULATION 22
23 CLINICAL ADVISORS RICHARD NORTH, MD CHIEF SCIENTIFIC ADVISOR GIANCARLO BAROLAT, MD CHIEF MEDICAL ADVISOR NEUROMODULATION 23
24 Indication: Spinal Cord Stimulation for the treatment of chronic pain of the trunk and limbs 24
25 WHY SPINAL CORD STIMULATION (SCS)? Largest neuromodulation market at $1.3 Billion (2010) High growth rate: 10% -14% projected CAGR Efficacy rates: 75% Established regulatory pathway Established reimbursement Strong ASPs Legacy of unmet clinical needs History of high value acquisitions NEUROMODULATION 25
26 STRUCTURE OF IP PORTFOLIO GREATBATCH 444 Patents 381 Foreign patents 657 Patents pending Internally generated intellectual property QiG GROUP Targeted patent activity at therapy, product, and device level ALGOSTIM Internally generated IP Clinician generated IP Greatbatch IP CLINICIAN IP Held exclusively by Algostim NEUROMODULATION 26
27 ALGOSTIM DEVELOPMENT MILESTONES Algostim Established Product Planning Product Design Product Evaluations & Testing PMA Market Availability NEUROMODULATION 27
28 28
GLOBAL NEUROSTIMULATION MARKET
GLOBAL NEUROSTIMULATION MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d
More informationBoston Scientific is advancing...
Boston Scientific is advancing... Our mission Our values Boston Scientific is dedicated to transforming lives through innovative Caring Meaningful Innovation High Performance medical solutions that improve
More informationForward Looking Statements and Further Information
JANUARY 2015 [ 1 ] Forward Looking Statements and Further Information SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than
More informationPhone: +44 (0) or BioPortfolio Limited
Europe Neuromodulation Devices Market by Procedure [Internal Stimulation (DBS, GES, SNS, SCS, VNS), and External Stimulation (TENS, TMS)], and by Geography Analysis & Forecast to 2019 Europe Neuromodulation
More informationDIRECT SPINAL THERAPEUTICS INC.
DIRECT SPINAL THERAPEUTICS INC. Novel Spinal Cord Modulation Platform Overview Presentation May 2014 Direct Spinal Therapeutics Inc. (DSTI) Proprietary Neuromodulation product/platform originated at Univ.
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationNeurostimulation Devices Market to 2018
Neurostimulation Devices Market to 2018 Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth GBI Research Report Guidance GBI Research Report
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationGeneral remarks on Neurorejuvenation Spinal Cord Stimulation (SCS) Program Occipital Nerve Stimulation Gamma-knife for Trigeminal Neuralgia
General remarks on Neurorejuvenation Spinal Cord Stimulation (SCS) Program Occipital Nerve Stimulation Gamma-knife for Trigeminal Neuralgia Deep brain Stimulation (DBS) Program Neuromodulation is a field
More informationhistorical perspective 78 outcomes 81 rationale 78 technique 79 81
Subject Index ALS, see Amyotrophic lateral sclerosis Altius Electric Nerve Block, extremity pain management 151, 152 Amputation, see Postamputation pain Amyotrophic lateral sclerosis (ALS), phrenic nerve
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: vagus_nerve_stimulation 6/1998 5/2017 5/2018 5/2017 Description of Procedure or Service Stimulation of the
More informationPACEMAKERS ARE NOT JUST FOR THE HEART! Ab Siadati MD
PACEMAKERS ARE NOT JUST FOR THE HEART! Ab Siadati MD WHAT IS DEEP BRAIN STIMULATION? WHY SHOULD YOU CONSIDER DBS SURGERY FOR YOUR PATIENTS? HOW DOES DBS WORK? DBS electrical stimulation overrides abnormal
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationMICROELECTRONIC MEDICAL IMPLANTS: PRODUCTS, TECHNOLOGIES & OPPORTUNITIES
MICROELECTRONIC MEDICAL IMPLANTS: PRODUCTS, TECHNOLOGIES & OPPORTUNITIES HLC016E May 2016 Andrew McWilliams Project Analyst ISBN: 1-62296-295-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationMediCult. DnB NOR 2008 Health Seminar. Life s Beginning in Safe Hands
MediCult DnB NOR 2008 Health Seminar Life s Beginning in Safe Hands Agenda I. Company and Market Overview II. Product and Pipeline Focus III. Financial Highlights IV. Future Developments Sept. 9, 2008
More informationCowen and Company Annual Healthcare Conference 2018
NEUROMODULATION Cowen and Company Annual Healthcare Conference 2018 Heart Valves March 13, 2018 CARDIAC SURGERY Safe Harbor Certain statements in this presentation, other than purely historical information,
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationSupplemental Appendix
Supplemental Appendix Appendix Table 1. Sub-Categorization of Medical Devices Included in Study Sample vel Medical Devices (N = 309) Cardiovascular Cardiac (ventricular) assist devices Cardiac prosthetic
More informationMEDICAL CANNABIS COMPANY
MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements
More informationFirst Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International
First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International Tom Hein, CFO Safe Harbor Statement Except for historical information contained herein, the statements
More informationBlood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595
Transparency Market Research Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample
More informationExpanding the boundaries of nutrition Luis Cantarell
Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationMedical Review Criteria Implantable Neurostimulators
Medical Review Criteria Implantable Neurostimulators Subject: Implantable Neurostimulators Effective Date: April 14, 2017 Authorization: Prior authorization is required for covered implantable stimulators
More informationInnovative Treatment Technologies and How They Are Changing Treatment Delivery. Jeremy Mann Senior Associate October 15, 2009
Innovative Treatment Technologies and How They Are Changing Treatment Delivery Jeremy Mann Senior Associate October 15, 2009 Faculty Ed Pigott, Ph.D., Principal, NeuroAdvantage, LLC Jeremy Mann, Senior
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More information2015 INS World Congress Exhibitors
2015 INS World Congress Exhibitors American Interventional Headache Society (AIHS) Booth 36 www.interventionalheadache.net AIHS is a national professional organization of physicians, dentists, health care
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationNEUROSCIENCE. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Neurology. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Neurology Medpace supports our sponsors who are advancing new neurological products by providing specialized expertise in the design and
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationInvestor Presentation 2018
NEUROMODULATION Investor Presentation 2018 June 6, 2018GERY CARDIAC SURGERY Safe Harbor Certain statements in this presentation, other than purely historical information, are forward-looking statements
More informationCognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationTable of Contents: JULY TH EDITION
Table of Contents: Table of Contents of the worldwide Orthopaedic Contract manufacturing Market 2016-2021 & Top 100 player profiles 275+ pages 450+ exhibits July 2017 5 th edition I- Worldwide orthopaedic
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationCommercial-Stage Bioelectronic Medicine Company 1 st FDA-cleared non-invasive vagus nerve stimulation platform therapy
Commercial-Stage Bioelectronic Medicine Company 1 st FDA-cleared non-invasive vagus nerve stimulation platform therapy 2018 electrocore. All rights reserved. 1 Disclaimer This presentation may contain
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationGlobal Spine Market with Focus on Spinal Fusion: Industry Analysis & Outlook ( )
Industry Research by Koncept Analytics Global Spine Market with Focus on Spinal Fusion: Industry Analysis & Outlook ----------------------------------------- (2017-2021) January 2018 Global Spine Market
More informationMEDTRONIC PAIN THERAPIES & BRAIN MODULATION INVESTOR BRIEFING JANUARY 17, 2019 NORTH AMERICAN NEUROMODULATION SOCIETY (NANS)
MEDTRONIC PAIN THERAPIES & BRAIN MODULATION INVESTOR BRIEFING NORTH AMERICAN NEUROMODULATION SOCIETY (NANS) JANUARY 17, 2019 RYAN WEISPFENNING VICE PRESIDENT INVESTOR RELATIONS FORWARD LOOKING STATEMENT
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationrtms Versus ECT The Future of Neuromodulation & Brain Stimulation Therapies
rtms Versus ECT The Future of Neuromodulation & Brain Stimulation Therapies rtms Treatment Equipment rtms Equipment Positioning of coil ECT & rtms Innovative Treatment Options for Patients Only a fraction
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationMedtronic International Ltd
This report will reflect on the Business Department of Student working for in terms of purpose, values and responsibilities to the company and the community in large. As well as, future standing of its
More informationAgreement to Acquire Spinal Kinetics, Inc. March 15, 2018
Agreement to Acquire Spinal Kinetics, Inc. 1 March 15, 2018 2 SAFE HARBOR STATEMENT AND USE OF NON GAAP MEASURES WHY SPINAL KINETICS? The Spinal Kinetics M6 artificial discs further round out Orthofix
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationPosition Specification
Position Specification Empirical Spine, Inc. Title: Vice President, Clinical & Regulatory Affairs Opportunity: The Vice President, Clinical & Regulatory Affairs will play a key role in the success of this
More informationMedia Kit. September 2017
Media Kit September 2017 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationMedical Device VSP Design & Manufacturing. Virtual Surgical Planning
Medical Device VSP Design & Manufacturing Virtual Surgical Planning Overview 3D printing technology is at an inflection point with the medical device industry rapidly adopting 3D printing technology. This
More informationSolutions For The Aging Spine
Solutions For The Aging Spine NASDAQ: ATEC February 2009 www.alphatecspine.com Slide 0 5818 El Camino Real, Carlsbad, CA 92008 www.alphatecspine.com Forward Looking Statements This presentation and our
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationRobotic Spine Surgery [TASE]: MZOR
Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.
More informationDECEMBER 10, 2015 FOUR SEASONS HOTEL LAS VEGAS, NV
North American Neuromodulation Society est 1994 NANS I 3 Invention, Investment, and Invigoration Summit THURSDAY, DECEMBER 10, 2015 FOUR SEASONS HOTEL LAS VEGAS, NV PLEASE JOIN US AT NANS I 3 The Annual
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationIndustry Research by Koncept Analytics
Industry Research by Koncept Analytics Global Transcatheter Mitral Valve Repair & Replacement (TMVR) Market: Industry Analysis & Outlook ----------------------------------------- (2018-2022) March 2018
More informationOventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane
Oventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane February 2018 Twitter: @OventusLtd About Oventus (ASX: OVN) Oventus is commercialising its Airway Technology
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationCompany Profile 2011
Company Profile 2011 Disclaimer This presentation contains forward-looking statements based on the currently held beliefs and assumptions of our management, which are expressed in good faith and in their
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationThe possibility of deep brain stimulation to treat eating disorders.
The possibility of deep brain stimulation to treat eating disorders. Andres M Lozano MD PhD Professor and Dan Family Chair of Neurosurgery Canada Research Chair in Neuroscience Toronto Western Hospital
More informationView Report Details. Global Coronary Stent Market
View Report Details Global Coronary Stent Market ------------------------------------------------- 2013 View Report Details Executive Summary Coronary heart diseases are nowadays becoming more and more
More informationThe UW Medicine Neurosciences Institute
The UW Medicine Neurosciences Institute is a multi-disciplinary team that diagnoses and treats disorders of the nervous system. Our physicians conduct world class research, and combine the latest technology
More informationInternational Neuromodulation Society 14th World Congress May 25-30, 2019, Preliminary Scientific Program*
Pre-Conference Days May 25-26 International Neuromodulation Society 14th World Congress May 25-30, 2019, Preliminary Scientific Program* *Subject to change May 25 - Pre-Conference: Noninvasive Brain Stimulation
More informationC ARDIAC INTERVENTION
CARDIAC INTERVENTION CARDIAC INTERVENTION FOCUS ACCESS We understand that you demand the best from yourself and from the companies you work with. Merit Medical s Cardiac Intervention business line delivers
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More information2015 Investor Conference
2015 Investor Conference ACCELERATING PROFITABLE GROWTH Jill Schaaf President, Renal Care Teeramanas Tanaekakarapong, ESRD Patient, Bangkok, Thailand Becoming The Global Leader In Renal Care Our Global
More informationOWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationEfficient Feature Extraction and Classification Methods in Neural Interfaces
Efficient Feature Extraction and Classification Methods in Neural Interfaces Azita Emami Professor of Electrical Engineering and Medical Engineering Next Generation Therapeutic Devices 2 Where We Started:
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationWorking at Boston Scientific. Ronan Emmett Human Resources
Working at Boston Scientific Ronan Emmett Human Resources 1 Our Company One of the World s Largest Medical Device Companies HQ: Natick, Boston 18 Manufacturing sites worldwide 24,000 people 13,000 products
More informationDealdoc Collaborative R&D and marketing agreement for diabetes product portfolio
Dealdoc Collaborative R&D and marketing agreement for diabetes product portfolio Bristol-Myers Squibb AstraZeneca Amylin Pharmaceuticals Jun 29 2012 Collaborative R&D and marketing agreement for diabetes
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationPSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development
THE POWER OFx Experts. Experience. Execution. A Deeper Dive into Psychiatry Incidences of mental disorders such as depression, bipolar, anxiety disorders, and schizophrenia continue to grow around the
More informationTREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal.
TREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal. MISSION & VISION Our mission is to develop more effective strategies and safer products
More informationJefferies 2010 Global Life Sciences Conference
Jefferies 2010 Global Life Sciences Conference VP Anders Rendtorff, Corporate Communications Forward-looking statements Page 2 The forward-looking statements contained in this presentation, including forecasts
More informationSorin Group. Marco Chiadò Piat, VP Corporate Development. Goldman Sachs European Medtech and Healthcare Services 5-6 September 2007
Sorin Group Marco Chiadò Piat, VP Corporate Development Goldman Sachs European Medtech and Healthcare Services 5-6 September 2007 Sorin FY 2006 results by Business Area FY 06 ( Mn) FY 06 vs FY 05 as reported
More informationEdwards Lifesciences. Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring
Edwards Lifesciences Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring Use of Non-GAAP Financial Measures Unless otherwise indicated, all figures are GAAP financial
More informationBuilding a Global Neurotoxin Franchise
JUNE 2, 2014 Building a Global Neurotoxin Franchise DAN BROWNE President & CEO Forward-Looking Statements This presentation contains forward-looking statements, including statements related to the process
More information